logo
logo
SGHT stock ticker logo

Sight Sciences, Inc.

NASDAQ•SGHT
CEO: Mr. Paul Badawi
Sector: Healthcare
Industry: Medical - Devices
Listing Date: 2021-07-15
Sight Sciences, Inc., an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork. It also offers TearCare System, a wearable eyelid technology for adult patients with evaporative dry eye disease due to meibomian gland dysfunction, as well as related components. It offers its products through sales representatives and distributors to hospitals, medical centers, and eyecare professionals in the United States. Sight Sciences, Inc. was incorporated in 2010 and is headquartered in Menlo Park, California.
Contact Information
4040 Campbell Avenue, Suite 100, Menlo Park, CA, 94025, United States
877-266-1144
www.sightsciences.com
Market Cap
$199.82M
P/E (TTM)
-5.1
26.9
Dividend Yield
--
52W High
$9.24
52W Low
$2.03
52W Range
23%
Rank64Top 94.9%
1.7
F-Score
Modified Piotroski Analysis
Based on 7-year fundamentals
Weak • 1.7 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2019-2025

Financial Dashboard

Q4 2025 Data

Revenue

$20.39M+0.00%
4-Quarter Trend

EPS

-$0.08+0.00%
4-Quarter Trend

FCF

-$1.67M+0.00%
4-Quarter Trend

2025 Annual Earnings Highlights

Key Highlights

Net Loss Reduction Net loss narrowed to 38.4M USD in 2025 from 51.5M USD in 2024, reflecting improved operational efficiency and cost management.
Operating Expense Control Total operating expenses decreased to 103.8M USD in 2025 from 118.8M USD in 2024, driven by restructuring and cost-saving initiatives.
Strong Cash Position Cash and cash equivalents totaled 92.0M USD as of December 31, 2025, supporting operations for at least the next 12 months.

Risk Factors

Reimbursement Coverage Uncertainty Medicare and private payor coverage policies for MIGS and TearCare procedures remain uncertain, potentially impacting future revenue and market adoption.
Manufacturing Concentration Risk Reliance on single-source manufacturers in China exposes operations to geopolitical tensions, trade disputes, and potential supply chain disruptions and costs.
Intense Market Competition Highly competitive glaucoma and dry eye markets with larger, well-capitalized rivals may pressure pricing and limit market share growth for products.

Outlook

Clinical Data Investment Continued investment in clinical trials and real-world evidence to support product efficacy, market access, and reimbursement for glaucoma and dry eye.
Manufacturing Footprint Diversification Expanding manufacturing capacity outside of China in 2026 to mitigate geopolitical risks and reduce exposure to potential future trade tariffs.
Strategic Market Expansion Focus on establishing OMNI and SION as standards of care and driving TearCare adoption through targeted commercial and educational initiatives.

Peer Comparison

Revenue (TTM)

OMI stock ticker logoOMI
$2.76B
-41.0%
VMD stock ticker logoVMD
$270.28M
+20.5%
CERS stock ticker logoCERS
$206.13M
+14.3%

Gross Margin (Latest Quarter)

PRQR stock ticker logoPRQR
100.0%
+0.0pp
OMI stock ticker logoOMI
93.9%
-2.1pp
MXCT stock ticker logoMXCT
92.4%
+16.1pp

Key Metrics

Symbol
Market Cap
P/E (TTM)
ROE (TTM)
Debt to Assets
VMD$352.17M23.110.9%7.4%
CERS$343.99M-21.8-26.4%43.7%
FBRX$342.99M-9.4-75.6%0.0%

Long-Term Trends

Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
5.2%
Steady Growth
4Q Net Income CAGR
N/M
Profitability Shift
Cash Flow Stability
0%
Cash Flow Needs Attention

Deep Research

Next earnings:May 6, 2026
|
EPS:-
|
Revenue:-
Financials
Earnings Calls
Reports
News
Income Statement
Balance Sheet
Cash Flow Statement
Ratios
% Chg.
Income Statement
LTM
No Data